Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Approval | 41 | 2024 | 820 | 8.870 |
Why?
|
United States Food and Drug Administration | 21 | 2024 | 1673 | 3.130 |
Why?
|
Technology Assessment, Biomedical | 10 | 2024 | 312 | 2.460 |
Why?
|
Product Surveillance, Postmarketing | 6 | 2022 | 463 | 2.380 |
Why?
|
Drug Industry | 9 | 2020 | 791 | 2.270 |
Why?
|
Medicare Part D | 5 | 2023 | 355 | 1.940 |
Why?
|
Randomized Controlled Trials as Topic | 22 | 2024 | 10384 | 1.900 |
Why?
|
Drug Costs | 8 | 2023 | 1195 | 1.860 |
Why?
|
Antineoplastic Agents | 19 | 2024 | 13643 | 1.630 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2019 | 3250 | 1.570 |
Why?
|
Negotiating | 2 | 2023 | 153 | 1.500 |
Why?
|
Drug and Narcotic Control | 4 | 2021 | 144 | 1.450 |
Why?
|
Research Design | 17 | 2022 | 6207 | 1.310 |
Why?
|
Equipment Safety | 2 | 2020 | 250 | 1.270 |
Why?
|
Device Approval | 3 | 2020 | 164 | 1.240 |
Why?
|
Pharmaceutical Preparations | 6 | 2022 | 1086 | 1.150 |
Why?
|
Evidence-Based Medicine | 11 | 2020 | 3692 | 1.140 |
Why?
|
State Medicine | 5 | 2024 | 219 | 1.120 |
Why?
|
Uterine Cervical Dysplasia | 4 | 2024 | 391 | 1.100 |
Why?
|
Patient Preference | 3 | 2024 | 946 | 1.020 |
Why?
|
Meta-Analysis as Topic | 6 | 2019 | 1365 | 0.930 |
Why?
|
Europe | 16 | 2023 | 3430 | 0.870 |
Why?
|
Neoplasms | 15 | 2024 | 22350 | 0.840 |
Why?
|
Drug Labeling | 2 | 2024 | 251 | 0.840 |
Why?
|
Conflict of Interest | 3 | 2023 | 556 | 0.800 |
Why?
|
Dyslipidemias | 3 | 2013 | 872 | 0.750 |
Why?
|
Quality-Adjusted Life Years | 4 | 2024 | 1740 | 0.750 |
Why?
|
Choice Behavior | 3 | 2024 | 846 | 0.740 |
Why?
|
Data Display | 1 | 2021 | 174 | 0.730 |
Why?
|
Exercise Therapy | 3 | 2019 | 938 | 0.670 |
Why?
|
Cost Control | 2 | 2023 | 628 | 0.650 |
Why?
|
Hypoglycemic Agents | 4 | 2015 | 3108 | 0.640 |
Why?
|
Cost-Benefit Analysis | 11 | 2024 | 5536 | 0.630 |
Why?
|
Safety | 2 | 2021 | 1157 | 0.630 |
Why?
|
Biomedical Technology | 2 | 2019 | 210 | 0.630 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2024 | 2039 | 0.610 |
Why?
|
Prescription Drugs | 2 | 2023 | 634 | 0.600 |
Why?
|
Comparative Effectiveness Research | 5 | 2020 | 713 | 0.580 |
Why?
|
United States | 33 | 2024 | 72951 | 0.570 |
Why?
|
Disclosure | 1 | 2023 | 755 | 0.560 |
Why?
|
Costs and Cost Analysis | 4 | 2019 | 1667 | 0.550 |
Why?
|
Clinical Trials as Topic | 6 | 2024 | 8045 | 0.550 |
Why?
|
Cost Sharing | 1 | 2020 | 409 | 0.540 |
Why?
|
England | 4 | 2024 | 533 | 0.510 |
Why?
|
Drug Prescriptions | 2 | 2022 | 1663 | 0.500 |
Why?
|
Cardiovascular Diseases | 9 | 2022 | 15657 | 0.490 |
Why?
|
Humans | 110 | 2024 | 766766 | 0.490 |
Why?
|
Marketing of Health Services | 2 | 2015 | 152 | 0.490 |
Why?
|
Equipment and Supplies | 1 | 2017 | 273 | 0.480 |
Why?
|
Cholesterol, LDL | 2 | 2014 | 2392 | 0.480 |
Why?
|
Accidents, Traffic | 3 | 2012 | 818 | 0.480 |
Why?
|
Health Services Accessibility | 4 | 2024 | 5514 | 0.470 |
Why?
|
Medication Therapy Management | 1 | 2015 | 131 | 0.460 |
Why?
|
Prescription Fees | 1 | 2014 | 153 | 0.420 |
Why?
|
Community Pharmacy Services | 3 | 2021 | 52 | 0.410 |
Why?
|
Cost of Illness | 4 | 2019 | 1949 | 0.410 |
Why?
|
Decision Support Techniques | 3 | 2020 | 2006 | 0.410 |
Why?
|
Antihypertensive Agents | 2 | 2019 | 2030 | 0.400 |
Why?
|
Drug Therapy | 1 | 2015 | 504 | 0.400 |
Why?
|
Waiting Lists | 1 | 2017 | 779 | 0.400 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2013 | 187 | 0.390 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1445 | 0.370 |
Why?
|
Prediabetic State | 2 | 2015 | 547 | 0.370 |
Why?
|
Endpoint Determination | 3 | 2020 | 592 | 0.370 |
Why?
|
Reimbursement, Incentive | 1 | 2016 | 541 | 0.360 |
Why?
|
Health Policy | 3 | 2021 | 2698 | 0.360 |
Why?
|
Glucosides | 1 | 2015 | 533 | 0.360 |
Why?
|
Coronary Disease | 3 | 2015 | 5915 | 0.360 |
Why?
|
Diuretics | 4 | 2020 | 614 | 0.350 |
Why?
|
Medication Adherence | 3 | 2022 | 2190 | 0.340 |
Why?
|
Conization | 3 | 2024 | 18 | 0.330 |
Why?
|
Primary Prevention | 2 | 2015 | 1188 | 0.320 |
Why?
|
Benzhydryl Compounds | 1 | 2015 | 944 | 0.310 |
Why?
|
Motorcycles | 1 | 2009 | 42 | 0.310 |
Why?
|
Drug Tolerance | 2 | 2020 | 365 | 0.300 |
Why?
|
Automobiles | 1 | 2009 | 103 | 0.300 |
Why?
|
Insurance Coverage | 5 | 2023 | 1945 | 0.300 |
Why?
|
Decision Making | 3 | 2020 | 3951 | 0.290 |
Why?
|
Quality Improvement | 2 | 2020 | 3850 | 0.280 |
Why?
|
Bicycling | 1 | 2009 | 177 | 0.280 |
Why?
|
Disabled Persons | 2 | 2014 | 1208 | 0.280 |
Why?
|
Erythropoietin | 1 | 2011 | 718 | 0.280 |
Why?
|
Cardiovascular Agents | 1 | 2013 | 849 | 0.280 |
Why?
|
Uncertainty | 5 | 2024 | 764 | 0.280 |
Why?
|
Secondary Prevention | 1 | 2013 | 1469 | 0.270 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2022 | 388 | 0.260 |
Why?
|
Chronic Disease | 3 | 2019 | 9357 | 0.260 |
Why?
|
Cerebrovascular Disorders | 1 | 2013 | 1479 | 0.260 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 2171 | 0.260 |
Why?
|
Government Regulation | 3 | 2020 | 525 | 0.250 |
Why?
|
Drug Discovery | 2 | 2015 | 1065 | 0.250 |
Why?
|
Lipids | 2 | 2013 | 3319 | 0.240 |
Why?
|
Treatment Outcome | 16 | 2024 | 65273 | 0.240 |
Why?
|
Quality of Life | 6 | 2024 | 13476 | 0.240 |
Why?
|
Blood Transfusion | 1 | 2011 | 1308 | 0.240 |
Why?
|
Multiple Sclerosis | 2 | 2010 | 3229 | 0.240 |
Why?
|
Efficiency | 1 | 2008 | 479 | 0.230 |
Why?
|
Pharmacists | 3 | 2021 | 261 | 0.230 |
Why?
|
Aortic Coarctation | 2 | 2017 | 278 | 0.230 |
Why?
|
Biomedical Research | 2 | 2020 | 3459 | 0.220 |
Why?
|
Professional Role | 3 | 2021 | 314 | 0.220 |
Why?
|
Health Behavior | 1 | 2015 | 2649 | 0.220 |
Why?
|
Automobile Driving | 1 | 2009 | 442 | 0.220 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2019 | 12245 | 0.220 |
Why?
|
Health Resources | 1 | 2010 | 951 | 0.220 |
Why?
|
Statistics as Topic | 3 | 2016 | 2351 | 0.220 |
Why?
|
Communication | 2 | 2023 | 3905 | 0.220 |
Why?
|
Heart Transplantation | 1 | 2017 | 3306 | 0.220 |
Why?
|
Colposcopy | 1 | 2024 | 151 | 0.210 |
Why?
|
Blood Pressure | 1 | 2018 | 8533 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3110 | 0.210 |
Why?
|
Health Care Costs | 3 | 2011 | 3242 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3232 | 0.200 |
Why?
|
Disability Evaluation | 1 | 2010 | 1827 | 0.200 |
Why?
|
Premature Birth | 3 | 2024 | 1830 | 0.200 |
Why?
|
Health Status | 1 | 2015 | 4087 | 0.200 |
Why?
|
Anemia | 1 | 2011 | 1514 | 0.200 |
Why?
|
Hypertension | 2 | 2019 | 8616 | 0.190 |
Why?
|
Exercise | 1 | 2018 | 5945 | 0.190 |
Why?
|
Pandemics | 2 | 2021 | 8735 | 0.190 |
Why?
|
Potassium Compounds | 1 | 2021 | 42 | 0.190 |
Why?
|
Patient Rights | 1 | 2021 | 126 | 0.180 |
Why?
|
Cognition Disorders | 1 | 2015 | 3967 | 0.180 |
Why?
|
Women's Health | 2 | 2022 | 2081 | 0.180 |
Why?
|
Activities of Daily Living | 1 | 2010 | 2429 | 0.180 |
Why?
|
Canrenone | 1 | 2020 | 5 | 0.180 |
Why?
|
Isolated Noncompaction of the Ventricular Myocardium | 1 | 2020 | 22 | 0.170 |
Why?
|
Markov Chains | 3 | 2013 | 974 | 0.170 |
Why?
|
Cyprus | 4 | 2024 | 96 | 0.170 |
Why?
|
Odds Ratio | 5 | 2022 | 9661 | 0.170 |
Why?
|
Pharmacy | 1 | 2021 | 92 | 0.170 |
Why?
|
Pharmacies | 1 | 2021 | 171 | 0.170 |
Why?
|
Nitrates | 1 | 2021 | 260 | 0.170 |
Why?
|
Survival Analysis | 3 | 2021 | 10100 | 0.160 |
Why?
|
Moral Obligations | 1 | 2020 | 91 | 0.160 |
Why?
|
Government Agencies | 1 | 2019 | 161 | 0.160 |
Why?
|
Wounds and Injuries | 2 | 2012 | 2513 | 0.160 |
Why?
|
Athletes | 2 | 2017 | 1161 | 0.160 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 161 | 0.160 |
Why?
|
Ethics, Research | 1 | 2020 | 178 | 0.160 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 2505 | 0.160 |
Why?
|
Policy | 1 | 2023 | 512 | 0.160 |
Why?
|
Germany | 4 | 2022 | 882 | 0.160 |
Why?
|
Lovastatin | 1 | 2019 | 114 | 0.160 |
Why?
|
Death, Sudden, Cardiac | 2 | 2017 | 1567 | 0.150 |
Why?
|
Access to Information | 1 | 2021 | 317 | 0.150 |
Why?
|
Technology, Pharmaceutical | 1 | 2018 | 83 | 0.150 |
Why?
|
Brazil | 1 | 2022 | 1249 | 0.150 |
Why?
|
Life Expectancy | 1 | 2024 | 1249 | 0.140 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2020 | 347 | 0.140 |
Why?
|
Stroke | 3 | 2015 | 9741 | 0.140 |
Why?
|
Sports Medicine | 2 | 2017 | 239 | 0.140 |
Why?
|
Pravastatin | 1 | 2019 | 391 | 0.140 |
Why?
|
International Cooperation | 2 | 2020 | 1434 | 0.130 |
Why?
|
Dementia | 2 | 2023 | 2741 | 0.130 |
Why?
|
Heart Failure | 3 | 2020 | 11882 | 0.130 |
Why?
|
Simvastatin | 1 | 2019 | 345 | 0.130 |
Why?
|
Research Report | 1 | 2019 | 367 | 0.130 |
Why?
|
Spironolactone | 1 | 2020 | 415 | 0.130 |
Why?
|
Health Services | 2 | 2012 | 755 | 0.130 |
Why?
|
Endometriosis | 1 | 2024 | 868 | 0.130 |
Why?
|
Cost Savings | 2 | 2017 | 902 | 0.120 |
Why?
|
Calcium Channel Blockers | 1 | 2018 | 687 | 0.120 |
Why?
|
Time Factors | 4 | 2024 | 40149 | 0.120 |
Why?
|
Administrative Personnel | 1 | 2016 | 185 | 0.120 |
Why?
|
Fertility | 1 | 2019 | 770 | 0.120 |
Why?
|
Delivery of Health Care | 4 | 2020 | 5368 | 0.120 |
Why?
|
Self Efficacy | 1 | 2019 | 643 | 0.120 |
Why?
|
Stents | 2 | 2017 | 3193 | 0.120 |
Why?
|
Rare Diseases | 1 | 2020 | 630 | 0.120 |
Why?
|
Female | 20 | 2024 | 396520 | 0.120 |
Why?
|
Patient Selection | 2 | 2018 | 4252 | 0.110 |
Why?
|
Retrospective Studies | 10 | 2024 | 81635 | 0.110 |
Why?
|
Policy Making | 2 | 2020 | 547 | 0.110 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 499 | 0.110 |
Why?
|
Data Interpretation, Statistical | 2 | 2014 | 2693 | 0.110 |
Why?
|
Economic Recession | 1 | 2014 | 79 | 0.110 |
Why?
|
Electrocardiography | 2 | 2017 | 6408 | 0.110 |
Why?
|
Random Allocation | 1 | 2017 | 2394 | 0.100 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2015 | 2763 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1445 | 0.100 |
Why?
|
Risk Assessment | 6 | 2020 | 24295 | 0.100 |
Why?
|
Antidepressive Agents | 1 | 2024 | 2903 | 0.100 |
Why?
|
Patient Care Management | 1 | 2015 | 302 | 0.100 |
Why?
|
Angioplasty, Balloon | 1 | 2016 | 591 | 0.100 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 1514 | 0.100 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2018 | 1065 | 0.100 |
Why?
|
Switzerland | 2 | 2022 | 322 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10745 | 0.090 |
Why?
|
Mass Screening | 2 | 2017 | 5454 | 0.090 |
Why?
|
Male | 13 | 2024 | 364142 | 0.090 |
Why?
|
Health Care Reform | 2 | 2017 | 1256 | 0.090 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2020 | 1188 | 0.090 |
Why?
|
Legislation, Drug | 1 | 2012 | 216 | 0.090 |
Why?
|
Research Support as Topic | 1 | 2014 | 697 | 0.090 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 26310 | 0.080 |
Why?
|
Risk Factors | 7 | 2020 | 74881 | 0.080 |
Why?
|
Psychometrics | 1 | 2019 | 3060 | 0.080 |
Why?
|
Medicare | 2 | 2021 | 6820 | 0.080 |
Why?
|
Anticoagulants | 2 | 2015 | 4855 | 0.080 |
Why?
|
Observation | 1 | 2010 | 310 | 0.080 |
Why?
|
Pregnancy Outcome | 1 | 2019 | 2971 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1946 | 0.080 |
Why?
|
Child Welfare | 1 | 2012 | 521 | 0.080 |
Why?
|
Aorta | 1 | 2016 | 2043 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9404 | 0.070 |
Why?
|
Life Tables | 1 | 2008 | 367 | 0.070 |
Why?
|
Contrast Media | 1 | 2021 | 5329 | 0.070 |
Why?
|
Regression Analysis | 1 | 2017 | 6329 | 0.070 |
Why?
|
Aged | 6 | 2024 | 171343 | 0.070 |
Why?
|
Monte Carlo Method | 1 | 2013 | 1250 | 0.070 |
Why?
|
Turkey | 1 | 2008 | 256 | 0.070 |
Why?
|
Medicaid | 1 | 2020 | 2836 | 0.070 |
Why?
|
Middle Aged | 6 | 2024 | 223257 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2024 | 59550 | 0.070 |
Why?
|
Young Adult | 5 | 2024 | 59939 | 0.060 |
Why?
|
Pilot Projects | 1 | 2019 | 8728 | 0.060 |
Why?
|
Income | 2 | 2019 | 1875 | 0.060 |
Why?
|
Respiration, Artificial | 1 | 2017 | 2727 | 0.060 |
Why?
|
Health Services Research | 1 | 2012 | 1811 | 0.060 |
Why?
|
Insurance, Health | 1 | 2017 | 2520 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2013 | 2354 | 0.060 |
Why?
|
Health Status Indicators | 1 | 2010 | 968 | 0.060 |
Why?
|
Pregnancy | 2 | 2024 | 30237 | 0.060 |
Why?
|
Mental Health Services | 1 | 2016 | 1728 | 0.060 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 1804 | 0.060 |
Why?
|
Adult | 8 | 2024 | 223307 | 0.060 |
Why?
|
Models, Economic | 2 | 2020 | 719 | 0.060 |
Why?
|
Cohort Studies | 5 | 2022 | 41710 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2533 | 0.060 |
Why?
|
Heart Diseases | 1 | 2016 | 2817 | 0.050 |
Why?
|
Health Promotion | 1 | 2015 | 2209 | 0.050 |
Why?
|
Length of Stay | 1 | 2017 | 6490 | 0.050 |
Why?
|
Prevalence | 2 | 2024 | 15835 | 0.050 |
Why?
|
Sex Distribution | 1 | 2008 | 2274 | 0.050 |
Why?
|
Developing Countries | 3 | 2023 | 2913 | 0.050 |
Why?
|
Mortality | 1 | 2013 | 2910 | 0.050 |
Why?
|
Age Distribution | 1 | 2008 | 2869 | 0.050 |
Why?
|
Contracts | 1 | 2022 | 60 | 0.050 |
Why?
|
Pelvic Pain | 1 | 2024 | 300 | 0.050 |
Why?
|
Employment | 1 | 2008 | 1110 | 0.050 |
Why?
|
Developed Countries | 1 | 2024 | 452 | 0.050 |
Why?
|
Canada | 2 | 2020 | 2126 | 0.040 |
Why?
|
Delayed Diagnosis | 1 | 2024 | 454 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2012 | 3561 | 0.040 |
Why?
|
Nervous System Diseases | 1 | 2010 | 1659 | 0.040 |
Why?
|
Infant, Newborn | 3 | 2022 | 26389 | 0.040 |
Why?
|
Adolescent | 6 | 2024 | 88904 | 0.040 |
Why?
|
Perinatal Mortality | 1 | 2019 | 103 | 0.040 |
Why?
|
Heart Function Tests | 1 | 2020 | 316 | 0.040 |
Why?
|
Medical Oncology | 2 | 2023 | 2340 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2021 | 685 | 0.040 |
Why?
|
Fetal Membranes, Premature Rupture | 1 | 2019 | 137 | 0.040 |
Why?
|
Industry | 1 | 2020 | 362 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2012 | 4306 | 0.040 |
Why?
|
Health Care Coalitions | 1 | 2017 | 36 | 0.040 |
Why?
|
World Health Organization | 1 | 2023 | 1327 | 0.030 |
Why?
|
Recurrence | 1 | 2010 | 8507 | 0.030 |
Why?
|
China | 1 | 2023 | 2383 | 0.030 |
Why?
|
Databases, Factual | 2 | 2023 | 8066 | 0.030 |
Why?
|
Antipsychotic Agents | 1 | 2010 | 3078 | 0.030 |
Why?
|
Pregnancy Rate | 1 | 2019 | 654 | 0.030 |
Why?
|
Suicide, Attempted | 1 | 2024 | 1413 | 0.030 |
Why?
|
Emergencies | 1 | 2021 | 1223 | 0.030 |
Why?
|
Sample Size | 1 | 2018 | 844 | 0.030 |
Why?
|
Infant, Low Birth Weight | 1 | 2019 | 870 | 0.030 |
Why?
|
Abortion, Spontaneous | 1 | 2019 | 536 | 0.030 |
Why?
|
Therapies, Investigational | 1 | 2015 | 110 | 0.030 |
Why?
|
Cryosurgery | 1 | 2019 | 478 | 0.030 |
Why?
|
Suicidal Ideation | 1 | 2024 | 1467 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2019 | 1012 | 0.030 |
Why?
|
Journal Impact Factor | 1 | 2015 | 157 | 0.030 |
Why?
|
Administration, Oral | 1 | 2021 | 4018 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2019 | 1437 | 0.030 |
Why?
|
Suicide | 1 | 2024 | 1606 | 0.030 |
Why?
|
Treatment Failure | 1 | 2019 | 2659 | 0.030 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 551 | 0.030 |
Why?
|
Disease Progression | 1 | 2010 | 13640 | 0.030 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2019 | 858 | 0.030 |
Why?
|
Laser Therapy | 1 | 2019 | 1108 | 0.020 |
Why?
|
Patient Admission | 1 | 2019 | 1364 | 0.020 |
Why?
|
Asia, Southeastern | 1 | 2012 | 115 | 0.020 |
Why?
|
Health Surveys | 1 | 2022 | 4055 | 0.020 |
Why?
|
Schizophrenia | 1 | 2010 | 6976 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2023 | 20144 | 0.020 |
Why?
|
North America | 1 | 2015 | 1287 | 0.020 |
Why?
|
Australia | 1 | 2015 | 1263 | 0.020 |
Why?
|
Child | 3 | 2024 | 80668 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2017 | 1313 | 0.020 |
Why?
|
Marketing | 1 | 2011 | 225 | 0.020 |
Why?
|
Algorithms | 1 | 2010 | 14072 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2021 | 4508 | 0.020 |
Why?
|
Africa South of the Sahara | 1 | 2012 | 751 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2015 | 998 | 0.020 |
Why?
|
Acute Coronary Syndrome | 1 | 2021 | 2186 | 0.020 |
Why?
|
Consensus | 1 | 2017 | 3208 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2021 | 12430 | 0.020 |
Why?
|
Reoperation | 1 | 2017 | 4325 | 0.020 |
Why?
|
Data Collection | 1 | 2015 | 3321 | 0.020 |
Why?
|
Long-Term Care | 1 | 2010 | 630 | 0.020 |
Why?
|
Infant | 1 | 2008 | 36461 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7841 | 0.020 |
Why?
|
Child, Preschool | 1 | 2008 | 42577 | 0.010 |
Why?
|
Motivation | 1 | 2015 | 2020 | 0.010 |
Why?
|
Depression | 1 | 2024 | 8228 | 0.010 |
Why?
|
Aortic Valve Stenosis | 1 | 2017 | 2023 | 0.010 |
Why?
|
Comorbidity | 1 | 2019 | 10580 | 0.010 |
Why?
|
Societies, Medical | 1 | 2015 | 3957 | 0.010 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3788 | 0.010 |
Why?
|
Health Personnel | 1 | 2015 | 3384 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39309 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7431 | 0.010 |
Why?
|
Prognosis | 1 | 2020 | 29948 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21525 | 0.010 |
Why?
|
Alzheimer Disease | 1 | 2019 | 8717 | 0.010 |
Why?
|